May 15, 2017


Novartis’s Entresto Voyage: Hindsight is 20/20

By Lucie Ellis

What caused Novartis’s innovative heart failure drug to falter, missing sales targets by $30m in 2016, and how is it expected to bounce back in 2017? Scrip explores Entresto’s journey and what this experience shows about the changing face of pharma’s customers.

read full article >